Why is Bausch + Lomb stock surging today?

Bausch + Lomb (BLCO) reported Q3 2026 earnings with 8% revenue growth to $1.375B, 34% adjusted EBITDA increase, and 23.6% margin. All segments grew: Pharmaceuticals +11%, Surgical +9%, Vision Care +6%. The company reduced net leverage to 4.1x and remains confident in meeting its 3-year plan targets.

Bausch + Lomb (BLCO) reported Q3 2026 revenue of $1.375B (+8% YoY), adjusted EBITDA of $325M (+34% YoY), and EPS of $0.34, beating estimates. The company raised full-year guidance, citing strong growth across all segments, particularly in dry eye treatments and premium IOLs. Shares rose 4.31% premarket.

Bausch + Lomb (BLCO) reported a Q3 2026 profit of $32M ($0.09/Share) vs. a loss last year, with revenue up 7% to $1.38B. Guidance raised: FY26 revenue now $5.45B-$5.55B, adjusted EBITDA $1.09B-$1.14B. Pre-market shares up 2.1%.

Bausch + Lomb (BLCO) reported Q3 2026 revenue of $1.38B, matching estimates and growing 7.3% YoY. Adjusted EPS of $0.34 beat estimates by 54.7%. Adjusted EBITDA was $325M, a 23.6% margin and 20% beat. The company raised full-year revenue guidance to $5.5B and EBITDA to $1.12B, both above estimates. Operating margin improved to 11.3%.

Bausch + Lomb reported Q3 2026 revenue of $1.375B, up 7% YoY, and net income of $32M. Adjusted EBITDA was $325M, and adjusted diluted EPS was $0.34. The company raised full-year revenue guidance to $5.45B–$5.55B and adjusted EBITDA guidance to $1.09B–$1.14B. All business segments grew, with notable increases in MIEBO and LUMIFY revenues.

Bausch + Lomb (BLCO) reported Q3 EPS of $0.34, beating estimates by $0.13, with revenue of $1.38B, slightly above expectations. The company forecasts FY 2026 revenue of $5.45B-$5.55B, below the analyst consensus of $5.49B. BLCO's stock is up 4.20% in the last 3 months and 13.90% in the last 12 months.